Virus maker Vibalogics plans expansion at German site as US growth plans underway – Endpoints News

A German virus-making CDMO is expanding its business in Europe by building an existing factory – and soon it will be its own owner, too.

Vibalogics has entered the first phase of a $ 50 million expansion of its Cuxhaven, Germany plant, the company said. It will also buy the site from the current owner.

CDMO specializes in the production of oncolytic viruses, viral vector vaccines and gene therapy products. The expansion will add an additional 100,000 square feet to the site for quality batch release and stability studies, drug product finishing and process development.

The site expansion will accommodate additional BSL-2 classified areas that feature 500-liter single-use bioreactors for virus-derived products, in order to effectively increase capacity. It will also have additional cell production suites and 32,000 square feet of harvesting, filtration and purification technology, as well as an additional 32,000 square feet of warehouse and office space.

Vibalogics President Stefan Beyer said in a press release:

The virotherapy sector is at an exciting phase in its journey. More and more companies are joining the industry, embarking on new projects with the potential to transform healthcare. We invest in our infrastructure, technologies and people in Cuxhaven to ensure we continue to meet the growing demand of the global market and provide the best possible service to our customers.

In November 2020, the company announced it would invest an additional $ 150 million in its 110,000 square foot factory in Boxborough, MA, with the goal of one day mass producing hundreds of gene and cell therapies. The announcement came about a year after Tom Hochuli came from Lonza to take over the management of the company.

This site should be up and running soon, the company said. It will employ around 100 staff and its first task will be to help evolve J & J’s AAV-based Covid-19 jab. Eventually, that focus will shift to remedies for cancer and rare diseases.

Source link

About Marion Alexander

Check Also

Global Presbyopia Correction Devices Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type and End Use – Industrial Computing

Global Presbyopia Correction Devices Market research is an intelligence report with meticulous efforts undertaken to …

Leave a Reply

Your email address will not be published. Required fields are marked *